Subgroup analysis of the non-interventional study VIVALDI: Agomelatine in treatment-naïve patients, in combination therapy and after treatment switch

References

• Chenu F, El Mansari M, Blier P. 2013. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 38:275–284.
   Google Scholar
• De Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. 2010. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628–642.
   PubMed Web of Science ®Google Scholar
• Fava M. 2004. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 65:27–32.
   PubMed Web of Science ®Google Scholar
• Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. 2010. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol. 25:305–314.
   PubMed Web of Science ®Google Scholar
• Hickie IB, Rogers NL. 2011. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 378:621–631.
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G. 2013. The efficacy of agomelatine in previously-treated depressed patients. Eur Neuropsychopharmacol. 23: 814–21.
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. 2010. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 71:109–120.
   PubMed Web of Science ®Google Scholar
• Kasper S, Hamon M. 2009. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 10:117–126.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. 2006. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 16:93–100.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S, Fulton K, Rasmussen J. 2008. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 28:329–333.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi SJ. 2010. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 24:479–499.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095–3105.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kim SY, Stewart R, Yoo JA, Bae KY, Jung SW, et al. 2011. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord 129:183–190.
   PubMed Web of Science ®Google Scholar
• Laredo J, Quera Salva MA, Falissard B, De Bodinat C. 2002. Screening of sleep and circadian rhythms in major depression. J Sleep Res 11:132–133.
   Google Scholar
• Laux G. 2012. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry 45:284–291.
   PubMed Web of Science ®Google Scholar
• Lemoine P, Guilleminault C, Alvarez E. 2007. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 68:1723–1732.
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D’Haenen H. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239–247.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopa minergic and adrenergic pathways. J Pharmacol Exp Ther 306: 954–964.
   PubMed Web of Science ®Google Scholar
• Möller HJ, Friede M, Schmauss M. 2007. Behandlung der Depression mit Escitalopram. Ergebnisse einer großen Anwendungsbeobachtung. Psychopharmakotherapie 14:149–156.
   Google Scholar
• Moller HJ, Schnitker J. 2007. [Prospective study using a modified Montgomery-Asberg Depression Scale]. Nervenarzt 78:685–690.
   Google Scholar
• Olie JP, Kasper S. 2007. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661–673.
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaer E. 2003. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694–703.
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, Guilleminault C. 2011. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 26:252–262.
   PubMed Web of Science ®Google Scholar
• Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, Tardito D. 2011. Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry 12:574–587.
   PubMed Web of Science ®Google Scholar
• Riemann D, Voderholzer U. 2003. Primary insomnia: a risk factor to develop depression. J Affect Disord 76:255–259.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Souetre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, et al. 1989. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 28:263–278.
   PubMed Web of Science ®Google Scholar
• Souetre E, Salvati E, Wehr TA, Sack DA, Krebs B, Darcourt G. 1988. Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. Am J Psychiatry 145:1133–1137.
   PubMed Web of Science ®Google Scholar
• Sparshatt A, McAllister Williams RH, Baldwin DS, Haddad PM, Bazire S, Weston E, et al. 2012. A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. Acta Psychiatr Scand.
   Google Scholar
• Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. 2010. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 71:616–626.
   PubMed Web of Science ®Google Scholar
• Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. 2009. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 70:344–353.
   PubMed Web of Science ®Google Scholar
• Thase ME. 1999. Antidepressant treatment of the depressed patient with insomnia. The J Clin Psychiatry 60:28–31; discussion 46–48.
   PubMed Web of Science ®Google Scholar
• Turek F. 2007. From circadian rhythms to clock genes in depression. Int Clin Psychopharmacol 22:1–8.
   PubMedGoogle Scholar
• Turek FW, Gillette MU. 2004. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 5:523–532.
   PubMed Web of Science ®Google Scholar
• Wehr TA, Wirz-Justice A. 1982. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 15:31–39.
   PubMedGoogle Scholar
• Wilson S, Argyropoulos S. 2005. Antidepressants and sleep: a qualitative review of the literature. Drugs 65:927–947.
   PubMed Web of Science ®Google Scholar
• Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP. 2001. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 14:19–28.
   PubMed Web of Science ®Google Scholar
• Wirz-Justice A. 2006. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 21:S11–15.
   PubMed Web of Science ®Google Scholar
• Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. 2010. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 30: 135–144.
   PubMed Web of Science ®Google Scholar